A Phase 1 interventional study of Pre-operative abemaciclib and Device for Cerebral Fluid Dialysate Collection in Glioma, sponsored by National Cancer Institute (NCI). Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 39 Years. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by National Cancer Institute (NCI) · Phase 1, Interventional, and Treatment
How we know · 7 judgments
Drug: Temozolomide · Diagnostic test: Brain MRI · Diagnostic test: Brain CT · Diagnostic test: EKG · Diagnostic test: Chest X-ray · Procedure: Biopsy/resection
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 112 studies testing temozolomide in Glioma — 13 open to participants now, 18 under way, 2 of them phase 3. Temozolomide · Glioma.
Among the 112 studies testing temozolomide in Glioma, this one is the 100th largest by enrollment of the 104 interventional ones that give a count, is one of 2 that started in 2023, is one of 34 in phase 1, reaches primary completion later than 1 of the 17 other live ones, and was the 98th registered.
1,456 studies on the registry are indexed under Glioma; 351 are open to participants now.
Browse Glioma studies →13 of the 112 studies testing temozolomide in Glioma are open now, in 10 countries. Recruiting first, the newest first:
Centre Leon Berard · Sites in France
Ages 12+
Mayo Clinic · Sites in United States
Ages 18+
University of Miami · Sites in United States
Ages 18+
Rigel Pharmaceuticals · Sites in United States, Australia, Canada and 4 more countries
Ages 12–39
The First Affiliated Hospital of Zhengzhou University · Sites in China
Ages 18–85
By country, each count listing its studies:
Temozolomide: first FDA approval 1999 (TEMODAR), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 267 Glioma studies recruiting now, 165 (62%) set no upper age limit and 57 (21%) stop at 75 or younger; 63 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 39 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
112 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 51 · Phase 2 68 · Phase 3 5 · Phase 4 1
First in 1998; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5 is below the median of 32 across 1,078 interventional studies indexed under Glioma.
Median enrollment 41 across the 104 interventional studies. Of the 80 that completed or were terminated, 33 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 112 have an industry lead sponsor. The 10 most frequent:
National Cancer Institute (NCI) is the lead sponsor of 3,557 studies on the registry; 335 are open to participants now.
Of its 412 completed or terminated interventional studies of FDA-regulated products, 374 (91%) have results posted.
80 studies in Glioma by National Cancer Institute (NCI): 3 open now, 21 under way, none of them phase 3. Of 57 finished, 23 (40%) have results posted.
Among the 80 studies in Glioma by National Cancer Institute (NCI), this one is the 60th largest by enrollment of the 66 interventional ones that give a count, is one of 2 that started in 2023, is one of 27 in phase 1, reaches primary completion later than 11 of the 20 other live ones, and was the 75th registered.
National Cancer Institute (NCI)’s Glioma studies by the year they started, since 1994.
5 of the studies testing temozolomide in Glioma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00978458Phase 3Eastern Cooperative Oncology GroupRadiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma | 2026-12-31 |
| NCT06258018Armando Santoro, MDNiraparib and Temozolomide in Patients Glioblastoma | 2026-12 |
| NCT05188508Memorial Sloan Kettering Cancer CenterPembrolizumab, Olaparib, and Temozolomide for People With Glioma | 2027-01 |
| NCT05030298Mayo ClinicPreoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial | 2027-03-15 |
| NCT07599371The First Affiliated Hospital of Zhengzhou UniversityA Prospective, Single-arm Clinical Study on the Safety and Efficacy of Ivoximab Combined With Temozolomide in the Treatment of Relapsed/Refractory Glioma | 2027-10-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 112 studies testing temozolomide in Glioma, from their registry updates:
Among National Cancer Institute (NCI)’s 80 in Glioma:
This tab as a report to print or save as PDF → With an account.
Background:
Diffuse midline gliomas are the most aggressive brain tumors of childhood and young adults. Most people with these tumors survive less than 2 years. Researchers want to see if an anticancer drug (abemaciclib) can help.
Objective:
To see if researchers can measure how much abemaciclib is in a person's brain tumor and brain fluid after they take the drug for a few days.
Eligibility:
People aged 18 to 39 with recurrent high-grade glioma or diffuse midline glioma.
Design:
Participants will be screened with:
Medical history
Physical exam
Blood and urine tests
Tests of heart function
Imaging scans of the brain, with a contrast agent
Screening tests will be repeated during the study. Participants will also have chest X-rays.
Participants will take abemaciclib by mouth twice a day for 4 and a half days.
Participants will undergo surgery. They will have either a tumor biopsy (a needle will be inserted to remove a small piece of tissue) or a surgical resection (part or all of the tumor will be removed). A small tube (catheter) will be placed in their brain for 48 hours to collect fluid samples. They will have a neurological exam every few hours while the tube is in place. Two days later, the tube will be removed without surgery. Participants will stay in the hospital for about 4 days for treatment.
Based on the results of abemaciclib levels in the brain, participants may keep taking abemaciclib and another drug (temozolomide) by mouth until their cancer gets worse or they have bad side effects. While taking these two drugs, participants will come back to the clinic for follow-up routinely. They will be followed by the study for life....
Background
Diffuse midline gliomas are the most aggressive brain tumors of childhood and young adults, with documented 2-year survival rates of \<10%. These tumors are infiltrative midline high-grade gliomas. Treatment failure is due in part to the presence of the blood-brain barrier (BBB), which limits permeability of varied agents.
Efforts to evaluate drug delivery across the BBB in midline gliomas have been restricted to post biopsy specimens. In comparison, intracerebral microdialysis sampling of cortical tissue has been shown to be a highly effective tool in determining cortical neuropharmacokinetics (brain extracellular fluid penetration, accumulation and excretion) intratumorally and peritumorally in adult brain tumor participants. Microdialysis is underutilized in the adult brain tumor setting to evaluate chemotherapy or targeted therapy permeability.
Within the United States (US), midline gliomas are not routinely biopsied. However, in the last several years, using modern surgical techniques, biopsy at the time of diagnosis has been performed with acceptable risks (4% mortality rate), with a feasible means to molecularly characterize the tumors; in order to identify potentially druggable targets.
One of the main attributes of disease progression/proliferation in midline gliomas is associated with dysregulation of the cell cycle. Cyclin-dependent kinase inhibitor 2A (CDKN2A) is the primary inhibitory brake on cyclin-dependent kinase 4 and 6 (CDK4/6) driven signaling and is commonly deleted in glioblastoma, pancreas, bladder, breast and prostate cancer. The specific CDK4/6 inhibitor, abemaciclib, has Food and Drug Administration (FDA) approval for the treatment of metastatic breast cancer.
This is a safety and feasibility study to evaluate pharmacokinetic and pharmacodynamic effects post abemaciclib administration in recurrent high grade glioma participants (cortical and midline tumors). We propose a trial using clinical microdialysis, placed in diffuse midline glioma tissue post biopsy, as an experimental research tool, to assess central nervous system (CNS) drug entry and targeted inhibition with abemaciclib. These studies are focused with the overall intent to inform future clinical therapies and preclinical modeling.
Objectives:
To evaluate safety and feasibility of intratumoral microdialysis placement post high grade glioma resection or midline glioma biopsy
To evaluate safety and feasibility of brain interstitial dialysate sampling in glioma participants post abemaciclib administration
To measure intratumoral vs. systemic concentrations of abemaciclib in glioma participants post abemaciclib administration
Eligibility:
Participants must have recurrent high-grade glioma or diffuse midline glioma based on clinical and/or radiologic findings
Participants with cortical high-grade gliomas must have previous intra-operative pathology confirming disease
Participants must be =>18 and \<= 39 years of age, at time of enrollment
Ability to swallow tablets/pills
Must have adequate organ function as per laboratory testing parameters
Abemaciclib administration must be able to begin no later than 14 days after the date of radiographic diagnosis (by T2 or fluid-attenuated inversion recovery (FLAIR) imaging)
Design:
This is a safety and feasibility study to evaluate tumor pharmacokinetics (PK) and pharmacodynamics (PD) of abemaciclib in recurrent high-grade glioma and midline glioma participants in need of surgical resection or biopsy, respectively.
All participants will take abemaciclib pre-operatively for 4.5 days (9 total doses of abemaciclib) at twice daily dosing.
A maximally safe surgical resection for cortical high-grade glioma or stereotactic needle biopsy for midline glioma will be performed in the operating room (OR). Microdialysis insertion (based on participant safety and surgical feasibility) will be performed post-biopsy in the OR and placement will be verified by brain computed tomography (CT).
Continuous microdialysis sampling will be obtained over the course of the next 48 hours, with subsequent removal of the catheter at the bedside.
After discharge from National Institutes of Health (NIH) inpatient, PK and PD findings will assist in determination of whether the participant will continue to receive abemaciclib therapy. If intratumoral or PK brain dialysate sampling concentrations are >10nmol/L, or PD findings suggest cyclin-dependent kinase (CDK) inhibition (decreased expression of Retinoblastoma protein (Rb) and/or topoisomerase II (topoII), then restart of abemaciclib therapy along with temozolomide will be administered for maintenance therapy post resection or biopsy.
Maintenance therapy will be abemaciclib 150mg po twice a day (BID) x 28 days together with temozolomide 200mg/m\^2 po daily x 5 days in 28-day cycles (temozolomide 150mg/m\^2 po daily x 5 days for cycle 1). After every 3 cycles, repeat brain magnetic resonance imaging's (MRIs) will be obtained to evaluate treatment response and disease progression.
If a participant starts to exhibit signs of clinical deterioration or radiographic progression, the participant will discontinue maintenance therapy, with ongoing contact for survival approximately every 6 months (+/- 14 days) until death.
Results of the PK measurements and molecular testing will be provided to the participant's home oncologist to provide for assistance with directed therapy decisions (outside of this investigational trial).
We propose to evaluate 5 participants. The accrual ceiling will be set at 17 participants to account for screen failures and inevaluable participants.
The criteria were revised on the registry on Oct 6, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must have recurrent high-grade glioma or midline glioma based on clinical and/or radiologic findings
Prior Therapies:
Hematologic Function: Participants must have an >=1500/microliters, >=9 g/dL (transfusion independent, defined as not receiving blood transfusion unless related to trauma or surgeries), and >=100,000/microliters (transfusion independent, defined as not receiving platelet transfusions unless related to trauma or surgeries)
Hepatic Function: Participants must have within 1.5 x the for age, with the exception of those with Gilbert syndrome, and (AST)/alanine aminotransferase (ALT) within \< 3 x upper limit of normal.
Renal Function: Participants must have a or radioisotope (GFR) >60ml/min/1.73 m\^2 or a normal serum creatinine.
Cardiac Function: Normal (echocardiogram (ECHO) or cardiac magnetic resonance imaging (MRI) >= 53% (or the institutional normal); (QTC) or Fridericia's corrected QT (QTcF) \< 450 msec.
The effects of abemaciclib on the developing human fetus are unknown, however cyclin-dependent kinase (CDK)-inhibiting agents are known to be teratogenic. Temozolomide is a cytotoxic chemotherapeutic agent which is known to be teratogenic. For these reasons, women of must agree to use a highly effective method of prior to study entry, for the duration of study participation, and for 3 weeks after the last dose of abemaciclib and 6 months after temozolomide. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation.
Highly effective contraception includes intrauterine devices (IUD), hormonal (birth control pills, injections, implants), tubal ligation, or partners vasectomy.
--Cases of pregnancy that occur during maternal exposures to abemaciclib should be reported. If a participant or spouse/partner is determined to be pregnant following abemaciclib initiation she must discontinue treatment immediately. Data on fetal outcomes and breastfeeding are to be collected for regulatory reporting and drug safety evaluation.
-Abemaciclib administration must be able to begin no later than 14 days after the date of radiographic diagnosis (by T2 or FLAIR imaging)
EXCLUSION CRITERIA:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Abemaciclib orally twice a day (BID) for 4.5 days followed by resection or biopsy and microdialysis catheter placement with continuous monitoring for 48 hours post-operative and genomic sampling of tissue/blood; followed by Arm 2/abemaciclib + temozolomide maintenance therapy.
Drug: Pre-operative abemaciclib · Device: Device for Cerebral Fluid Dialysate Collection · Device: Ashion Analytics GEM ExTra · Drug: abemaciclib + temozolomide · Drug: Temozolomide · Diagnostic Test: Brain MRI · Diagnostic Test: Brain CT · Diagnostic Test: EKG · Diagnostic Test: Chest X-ray · Procedure: Biopsy/resection
Maintenance therapy is abemaciclib 150mg by mouth (PO) BID x 28 days + temozolomide 200mg/m\^2 PO daily x 5 days in 28-day cycles (temozolomide 150mg/m\^2 PO daily x 5 days for cycle 1).
Drug: Pre-operative abemaciclib · Device: Device for Cerebral Fluid Dialysate Collection · Device: Ashion Analytics GEM ExTra · Drug: abemaciclib + temozolomide · Drug: Temozolomide · Diagnostic Test: Brain MRI · Diagnostic Test: Brain CT · Diagnostic Test: EKG · Diagnostic Test: Chest X-ray · Procedure: Biopsy/resection
Pre-operatively for 4.5 days; 200mg twice daily (9 total doses)
Also known as: Verzenio
Post-resection or post-biopsy continuous intracerebral microdialysis sampling for 48 hours to assess central nervous system (CNS) drug entry and targeted inhibition with abemaciclib
Resection/biopsy genomic sampling of tumor tissue and blood to identify therapeutic targets
Also known as: Ashion Analytics Genomic Enabled Medicine Exome and Transcriptome
Drug pages: AbemaciclibStudies of AbemaciclibAbemaciclib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · TemozolomideStudies of TemozolomideTemozolomide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Abemaciclib 150mg by mouth (po) twice a day (BID) and temozolomide 200mg/m\^2 po daily x 5 days in 28-day cycles (temozolomide 150mg/m\^2 po daily x 5 days for cycle 1)
Also known as: Verzenio + Temodar
Temozolomide 150mg/m\^2 by mouth (po) daily x 5 days for cycle 1
Also known as: Temodar
Screening (within 14 days prior to enrollment), baseline (within 14 days of first dose), as clinically indicated at catheter removal Day 7 (\>48 hours post op), maintenance therapy (after every 3 cycles), and post treatment (safety and long-term follow-up) as clinically indicated.
Also known as: Brain magnetic resonance imaging
Microdialysis (catheter in place) Day 5 and Day 6, and as clinically indicated at catheter removal Day 7 (\>48 hours post op).
Also known as: Brain computed tomography
Screening (within 14 days prior to enrollment), baseline (within 14 days of first dose), and as clinically indicated at catheter removal Day 7 (\>48 hours post op).
Also known as: Electrocardiogram
Baseline (within 14 days of first dose), and as clinically indicated at catheter removal Day 7 (\>48 hours post op).
Also known as: CXR
Microdialysis (catheter in place) Day 5 and Day 6.
Also known as: Bx/resection
Percentage of Participants Who Have Adequate Intra-tumoral Sampling Reported With an 80% Confidence Interval
The percentage of participants who have adequate intra-tumoral sampling was determined and reported with an 80% confidence interval. Adequate intra-tumoral tissue concentration is \<10nmol/L. Intra-tumoral sampling was performed by microdialysis.
Time frame: At surgery (less than 14 hours from surgery), biopsy (after 4 days of abemaciclib), and 2, 6, 10, 14, 18, 22, 26, 30, 34, 38,40, 44, and 48 hours post catheter insertion
Percentage of Participants Who Have Adequate Intra-tumoral Sampling Reported With a 95% Confidence Interval
The percentage of participants who have adequate intra-tumoral sampling was determined and reported with a 95% confidence interval. Adequate intra-tumoral tissue concentration is \<10nmol/L. Intra-tumoral sampling was performed by microdialysis.
Time frame: At surgery (less than 14 hours from surgery), biopsy (after 4 days of abemaciclib), and 2, 6, 10, 14, 18, 22, 26, 30, 34, 38,40, 44, and 48 hours post catheter insertion
Number of Participants Who Experience Any Type Grade 1, 2, 3, 4, and/or 5 Adverse Event (AE)/Complication Possibly, Probably, and/or Definitely Related to Adverse Events for Participants (pt) Receiving Abemaciclib
AEs were assessed by the Common Terminology Criteria for Adverse Events v5.0. A non-serious AE is any untoward medical occurrence. A serious AE is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the pt or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 1:mild. Grade 2: moderate. Grade 3: severe. Grade 4: life-threatening. Grade 5: death related to adverse event. All participants who receive at least 1 dose of abemaciclib or undergo the procedure to place the catheter will have their safety information reported. This table is related to AEs from abemaciclib therapy(pre-surgery). Values in the table will and should be different than other AE tables based on toleration of therapy at varied times for each pt.
Time frame: Study Day 1 through 30 days after the last intervention through study completion, an average of 4.5 months
Number of Grade 1, 2, 3, 4, and/or 5 Adverse Events (AE) At Least Possibly Related Adverse Events for Participants(pt) Receiving Combination Therapy With Abemaciclib and Temozolomide
AEs were assessed by the Common Terminology Criteria for AEs (CTCAE v5.0). A non-serious AE is any untoward medical occurrence. A serious AE is an adverse event or suspected adverse reaction that results in death, life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 1: mild. Grade 2: moderate. Grade 3: severe. Grade: 4 life-threatening. Grade 5: death related to AE. All participants who receive at least 1 dose of abemaciclib or undergo the procedure to place the catheter are reported. This table is related to AEs from abemaciclib post-surgery,given during maintenance cycle with temozolomide. Values in the table will and should be different than other AE tables based on toleration of therapy at varied times for each pt.
Time frame: Study Day 1 through 30 days after the last intervention through study completion, an average of 4.5 months
Time to Maximum Observed Plasma Concentration an Hour (Tmax(hr) of Drug Abemaciclib
Blood samples were collected to determine the time to maximum observed plasma concentration an hour (Tmax(hr) of drug abemaciclib. Abemaciclib levels in plasma were measured by Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) analysis.
Time frame: Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib
Maximum Plasma Concentration (Cmax) of Drug Abemaciclib
Blood samples were collected to determine the maximum plasma concentration of drug abemaciclib. Abemaciclib levels in plasma were measured by Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) analysis.
Time frame: Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib
Area Under the Plasma Concentration (AUC) of Drug Abemaciclib
AUC is a measure of the drug plasma serum concentration of abemaciclib over time. It is used to characterize drug absorption. Abemaciclib levels in plasma were measured by Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) analysis.
Time frame: Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib
Maximum Plasma Concentration (Cmax) of Unbound Abemaciclib
Unbound abemaciclib plasma exposure was calculated by the total drug exposure multiplied by the mean unbound fraction (fu,0.06) in human plasma.
Time frame: Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib
Area Under the Plasma Concentration (AUC) of Unbound Abemaciclib
AUC is a measure of the total drug plasma serum concentration of abemaciclib over time. It is used to characterize drug absorption. Unbound abemaciclib plasma exposure was calculated by the total drug exposure multiplied by the mean unbound fraction (fu,0.06) in human plasma.
Time frame: Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib
Time to Maximum Observed Plasma Concentration an Hour (Tmax(hr) of Brain Dialysate
Urea concentrations in blood and brain interstitial fluid were measured at timed intervals. Abemaciclib levels in plasma, brain tissue and dialysate were measured and compared by Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) analysis to determine plasma concentration.
Time frame: Approximately 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 40, 44, and 48 hours post catheter insertion
Maximum Plasma Concentration (Cmax) of Brain Dialysate
Blood and brain interstitial fluid were obtained via microdialysis catheter in the brain and urea (metabolite) concentrations in blood and brain interstitial fluid were measured at timed intervals. Abemaciclib levels in plasma, brain tissue and dialysate were measured by Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) to determine plasma concentration of drug in the brain.
Time frame: 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 40, 44, and 48 hours post catheter insertion
Area Under the Plasma Concentration (AUC) of Brain Dialysate
AUC is a measure of the total drug plasma serum concentration of abemaciclib over time. Blood and brain interstitial fluid were obtained via microdialysis catheter in the brain and urea (metabolite) concentrations in blood and brain interstitial fluid were measured at timed intervals. Abemaciclib levels in plasma, brain tissue and dialysate were measured by Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) analysis to determine concentration of drug in the brain.
Time frame: Approximately 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 40, 44, and 48 hours post catheter insertion
Concentration of Total Drug Abemaciclib From Tissue Obtained Via Brain Biopsy
Biopsied tumor tissue was obtained using a stereotactic needle in the brain. A minimum of 6 samples were taken and analyzed by liquid chromatography tandem mass spectrometry (LC/MS/MS) to determine drug concentrations in the brain tissue.
Time frame: 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 40, 44, and 48 hours post catheter insertion
Brain Biopsy Sampling Time
Brain biopsy sampling time is the timing of when the tumor tissue was biopsied since the last dose of abemaciclib.
Time frame: 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 40, 44, and 48 hours post catheter insertion
Ratio of Area Under the Plasma Concentration (AUC) in Brain Dialysate to Unbound Drug Abemaciclib AUC in Plasma
AUC is a measure of the total drug plasma serum concentration of abemaciclib over time. Unbound abemaciclib plasma exposure was calculated by the total drug exposure multiplied by the mean unbound fraction (fu,0.06) in human plasma. Abemaciclib levels in plasma, brain tissue and dialysate were measured by Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) analysis.
Time frame: Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib
Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)
Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.
Time frame: From the first study intervention, Study Day 1 through 30 days after the last abemaciclib administration, a range of every 28 ± 3 days, up to an average of 5 months.
| Milestone | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy |
|---|---|---|---|---|
| Started | 1 | 1 | 1 | 2 |
| Pre-op abemaciclib dosing 4.5 days | 1 | 1 | 0 | 2 |
| Resection or biopsy/microdialysis catheter placement | 1 | 1 | 0 | 2 |
| 48 hours - catheter removal | 1 | 1 | 0 | 2 |
| Abemaciclib >10nmol/l or cyclin-dependent kinase (cdk) inhibition | 1 | 1 | 0 | 2 |
| Start maintenance therapy | 0 | 1 | 0 | 2 |
| Completed | 1 | 1 | 0 | 2 |
| Not completed | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 |
The percentage of participants who have adequate intra-tumoral sampling was determined and reported with an 80% confidence interval. Adequate intra-tumoral tissue concentration is \<10nmol/L. Intra-tumoral sampling was performed by microdialysis.
| percentage of participants | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy |
|---|---|---|---|---|
| Percentage of Participants Who Have Adequate Intra-tumoral Sampling Reported With an 80% Confidence Interval | 100 (NA to NA) | 100 (NA to NA) | — | 100 (44.7 to 100) |
The percentage of participants who have adequate intra-tumoral sampling was determined and reported with a 95% confidence interval. Adequate intra-tumoral tissue concentration is \<10nmol/L. Intra-tumoral sampling was performed by microdialysis.
| percentage of participants | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy |
|---|---|---|---|---|
| Percentage of Participants Who Have Adequate Intra-tumoral Sampling Reported With a 95% Confidence Interval | 100 (NA to NA) | 100 (NA to NA) | — | 100 (15.8 to 100) |
AEs were assessed by the Common Terminology Criteria for Adverse Events v5.0. A non-serious AE is any untoward medical occurrence. A serious AE is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the pt or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 1:mild. Grade 2: moderate. Grade 3: severe. Grade 4: life-threatening. Grade 5: death related to adverse event. All participants who receive at least 1 dose of abemaciclib or undergo the procedure to place the catheter will have their safety information reported. This table is related to AEs from abemaciclib therapy(pre-surgery). Values in the table will and should be different than other AE tables based on toleration of therapy at varied times for each pt.
| Participants | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy |
|---|---|---|---|---|
| Grade 1 Abdominal/stomach pain | 1 | 0 | 0 | 1 |
| Grade 2 Anemia | 1 | 0 | 0 | 0 |
| Grade 3 Anemia | 1 | 0 | 0 | 0 |
| Grade 1 Bilirubin increased | 1 | 0 | 0 | 0 |
| Grade 1 Constipation | 1 | 0 | 0 | 0 |
| Grade 1 Creatinine increased | 1 | 0 | 0 | 1 |
| Grade 1 Diarrhea | 1 | 0 | 0 | 1 |
| Grade 2 Dyspepsia | 0 | 0 | 0 | 1 |
| Grade 1 Fatigue | 1 | 1 | 0 | 0 |
| Grade 1 Headache | 1 | 0 | 0 | 0 |
| Grade 1 Hypokalemia | 0 | 0 | 0 | 1 |
| Grade 1 Hypophosphatemia | 0 | 0 | 0 | 1 |
| Grade 2 Insomnia | 0 | 0 | 0 | 1 |
| Grade 1 Lethargy | 1 | 0 | 0 | 0 |
| Grade 2 Lymphopenia | 1 | 0 | 0 | 0 |
| Grade 3 Lymphopenia | 1 | 0 | 0 | 0 |
| Grade 1 Nausea | 1 | 1 | 0 | 0 |
| Grade 1 Thrombocytopenia | 0 | 1 | 0 | 0 |
| Grade 1 Vomiting | 1 | 0 | 0 | 0 |
| No Grade 4 and 5 Related to Drug | 0 | 0 | 0 | 0 |
AEs were assessed by the Common Terminology Criteria for AEs (CTCAE v5.0). A non-serious AE is any untoward medical occurrence. A serious AE is an adverse event or suspected adverse reaction that results in death, life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 1: mild. Grade 2: moderate. Grade 3: severe. Grade: 4 life-threatening. Grade 5: death related to AE. All participants who receive at least 1 dose of abemaciclib or undergo the procedure to place the catheter are reported. This table is related to AEs from abemaciclib post-surgery,given during maintenance cycle with temozolomide. Values in the table will and should be different than other AE tables based on toleration of therapy at varied times for each pt.
| adverse events | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy |
|---|---|---|
| Grade 1 Anemia | 0 | 1 |
| Grade 1 Creatinine increased | 0 | 1 |
| Grade 1 Diarrhea | 0 | 1 |
| Grade 1 Dyspepsia | 1 | 0 |
| Grade 2 Dyspepsia | 0 | 1 |
| Grade 1 Fatigue | 1 | 0 |
| Grade 2 Lymphopenia | 0 | 1 |
| Grade 3 Lymphopenia | 0 | 1 |
| Grade 1 Myalgia | 1 | 0 |
| Grade 1 Nausea | 1 | 1 |
| Grade 1 Neutrophil decreased | 1 | 0 |
| Grade 2 Neutrophil decreased | 1 | 1 |
| Grade 1 WBC decreased | 1 | 0 |
| Grade 2 WBC decreased | 1 | 1 |
| Grade 1 Scalp pain | 0 | 1 |
| No Grade 4 and 5 Related to Drug | 0 | 0 |
Blood samples were collected to determine the time to maximum observed plasma concentration an hour (Tmax(hr) of drug abemaciclib. Abemaciclib levels in plasma were measured by Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) analysis.
| hr | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy |
|---|---|---|---|---|
| Time to Maximum Observed Plasma Concentration an Hour (Tmax(hr) of Drug Abemaciclib | 7.02 ± 3.76 | 0.38 ± 3.76 | — | 8.05 ± 3.76 |
Blood samples were collected to determine the maximum plasma concentration of drug abemaciclib. Abemaciclib levels in plasma were measured by Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) analysis.
| nM | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy |
|---|---|---|---|---|
| Maximum Plasma Concentration (Cmax) of Drug Abemaciclib | 378.2 ± 40.34 | 360 ± 40.34 | — | 323.25 ± 40.34 |
AUC is a measure of the drug plasma serum concentration of abemaciclib over time. It is used to characterize drug absorption. Abemaciclib levels in plasma were measured by Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) analysis.
| hr*nM | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy |
|---|---|---|---|---|
| Area Under the Plasma Concentration (AUC) of Drug Abemaciclib | 9018.9 ± 723.7 | 10153.8 ± 723.7 | — | 9413.3 ± 723.7 |
Unbound abemaciclib plasma exposure was calculated by the total drug exposure multiplied by the mean unbound fraction (fu,0.06) in human plasma.
| nM | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy |
|---|---|---|---|---|
| Maximum Plasma Concentration (Cmax) of Unbound Abemaciclib | 22.69 ± 2.42 | 21.6 ± 2.42 | — | 19.39 ± 2.42 |
AUC is a measure of the total drug plasma serum concentration of abemaciclib over time. It is used to characterize drug absorption. Unbound abemaciclib plasma exposure was calculated by the total drug exposure multiplied by the mean unbound fraction (fu,0.06) in human plasma.
| hr*nM | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy |
|---|---|---|---|---|
| Area Under the Plasma Concentration (AUC) of Unbound Abemaciclib | 541.13 ± 43.42 | 609.23 ± 43.42 | — | 564.8 ± 43.42 |
Urea concentrations in blood and brain interstitial fluid were measured at timed intervals. Abemaciclib levels in plasma, brain tissue and dialysate were measured and compared by Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) analysis to determine plasma concentration.
| hr | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy |
|---|---|---|---|---|
| Time to Maximum Observed Plasma Concentration an Hour (Tmax(hr) of Brain Dialysate | 7.0 ± 2.28 | 11.0 ± 2.28 | — | 10.9 ± 2.28 |
Blood and brain interstitial fluid were obtained via microdialysis catheter in the brain and urea (metabolite) concentrations in blood and brain interstitial fluid were measured at timed intervals. Abemaciclib levels in plasma, brain tissue and dialysate were measured by Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) to determine plasma concentration of drug in the brain.
| nM | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy |
|---|---|---|---|---|
| Maximum Plasma Concentration (Cmax) of Brain Dialysate | 7.5 ± 53.72 | 19.1 ± 53.72 | — | 105.8 ± 53.72 |
AUC is a measure of the total drug plasma serum concentration of abemaciclib over time. Blood and brain interstitial fluid were obtained via microdialysis catheter in the brain and urea (metabolite) concentrations in blood and brain interstitial fluid were measured at timed intervals. Abemaciclib levels in plasma, brain tissue and dialysate were measured by Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) analysis to determine concentration of drug in the brain.
| hr*nM | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy |
|---|---|---|---|---|
| Area Under the Plasma Concentration (AUC) of Brain Dialysate | 148.2 ± 673.48 | 440.30 ± 673.48 | — | 1433.0 ± 673.48 |
Biopsied tumor tissue was obtained using a stereotactic needle in the brain. A minimum of 6 samples were taken and analyzed by liquid chromatography tandem mass spectrometry (LC/MS/MS) to determine drug concentrations in the brain tissue.
| nM | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy |
|---|---|---|---|---|
| Concentration of Total Drug Abemaciclib From Tissue Obtained Via Brain Biopsy | 3387.77 ± 1296.82 | 2202.0 ± 1296.82 | — | 1343.0 ± 1296.82 |
Brain biopsy sampling time is the timing of when the tumor tissue was biopsied since the last dose of abemaciclib.
| hr | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy |
|---|---|---|---|---|
| Brain Biopsy Sampling Time | 6.67 (0 to 48) | 5.24 (0 to 48) | — | 4.33 (0 to 48) |
AUC is a measure of the total drug plasma serum concentration of abemaciclib over time. Unbound abemaciclib plasma exposure was calculated by the total drug exposure multiplied by the mean unbound fraction (fu,0.06) in human plasma. Abemaciclib levels in plasma, brain tissue and dialysate were measured by Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) analysis.
| Ratio | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy |
|---|---|---|---|---|
| Ratio of Area Under the Plasma Concentration (AUC) in Brain Dialysate to Unbound Drug Abemaciclib AUC in Plasma | 0.27 ± 1.31 | 0.72 ± 1.31 | — | 2.73 ± 1.31 |
Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.
| Participants | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy |
|---|---|---|---|---|
| Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | 1 | 1 | 0 | 2 |
Collected over All-Cause Mortality and Adverse Events were monitored/assessed from the first study intervention, Study Day 1 through 30 days after the last abemaciclib administration, a range of every 28 ± 3 days, up to an average of 5 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) |
| Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) |
| Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery | — | — | — |
| Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy | 1/2 (50%) | 1/2 (50%) | 2/2 (100%) |
| Event | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy |
|---|---|---|---|---|
| Abdominal painGastrointestinal disorders | 1/1 | 0/1 | — | 0/2 |
| AnemiaBlood and lymphatic system disorders | 1/1 | 0/1 | — | 0/2 |
| AnxietyPsychiatric disorders | 1/1 | 0/1 | — | 0/2 |
| Blood and lymphatic system disorders - Other, specify: Fe def.Blood and lymphatic system disorders | 1/1 | 0/1 | — | 0/2 |
| ConstipationGastrointestinal disorders | 1/1 | 0/1 | — | 0/2 |
| DiarrheaGastrointestinal disorders | 1/1 | 1/1 | — | 0/2 |
| Disease progressionGeneral disorders | 1/1 | 0/1 | — | 0/2 |
| DyspepsiaGastrointestinal disorders | 0/1 | 1/1 | — | 0/2 |
| DysphasiaNervous system disorders | 1/1 | 0/1 | — | 0/2 |
| Facial muscle weaknessNervous system disorders | 1/1 | 0/1 | — | 0/2 |
| Event | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy |
|---|---|---|---|---|
| AlopeciaMetabolism and nutrition disorders | 0/1 | 1/1 | — | 0/2 |
| AnemiaBlood and lymphatic system disorders | 1/1 | 0/1 | — | 1/2 |
| AnorexiaMetabolism and nutrition disorders | 1/1 | 1/1 | — | 0/2 |
| Blood bicarbonate decreasedInvestigations | 1/1 | 0/1 | — | 0/2 |
| Blood bilirubin increasedInvestigations | 1/1 | 0/1 | — | 0/2 |
| BruisingInjury, poisoning and procedural complications | 0/1 | 1/1 | — | 0/2 |
| ConstipationGastrointestinal disorders | 0/1 | 1/1 | — | 1/2 |
| Creatinine increasedInvestigations | 1/1 | 0/1 | — | 1/2 |
| DepressionPsychiatric disorders | 0/1 | 1/1 | — | 0/2 |
| Dry skinSkin and subcutaneous tissue disorders | 0/1 | 1/1 | — | 0/2 |
| Age, Categorical(Participants) | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 1 | 1 | 2 | 5 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy | Total |
|---|---|---|---|---|---|
| Mean | 28 | 22 | 27 | 28.5 ± 9.19 | 26.8 ± 5.36 |
| Sex: Female, Male(Participants) | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy | Total |
|---|---|---|---|---|---|
| Female | 1 | 0 | 0 | 1 | 2 |
| Male | 0 | 1 | 1 | 1 | 3 |
| Ethnicity (NIH/OMB)(Participants) | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 1 | 1 | 0 | 1 | 3 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 | 2 |
| Race (NIH/OMB)(Participants) | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 1 | 1 | 1 | 1 | 4 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 1 |
| Region of Enrollment(participants) | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy | Total |
|---|---|---|---|---|---|
| United States | 1 | 1 | 1 | 2 | 5 |
| Tumor Type(Participants) | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy | Total |
|---|---|---|---|---|---|
| Astrocytoma, isocitrate dehydrogenase (IDH) mutant | 0 | 1 | 0 | 0 | 1 |
| Diffuse hemispheric glioma, glycine to arginine/valine at codon 34 (G34)- mutant | 1 | 0 | 1 | 1 | 3 |
| Diffuse midline glioma, histone H3 lysine 27 (H3K27)-altered | 0 | 0 | 0 | 1 | 1 |
| Previous Lines of Treatment(Participants) | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery | Arm 1 Cortical High-Grade Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery | Arm 2 Diffuse Midline Glioma: Abemaciclib + Surgery + Temozolomide & Maintenance Therapy | Total |
|---|---|---|---|---|---|
| 1 | 1 | 0 | 0 | 0 | 1 |
| 2 | 0 | 1 | 1 | 0 | 2 |
| 3 | 0 | 0 | 0 | 2 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All individual participant data (IPD) recorded in the medical record will be shared with intramural investigators upon request. In addition, all large-scale genomic sequencing data will be shared with subscribers to the database of Genotypes and Phenotypes (dbGaP).
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Clinical data available during the study and indefinitely. Genomic data will be shared from the time of upload to the database of Genotypes and Phenotypes (dbGaP).
Access criteria: Clinical data will be made available via subscription to Biomedical Translational Research Information System (BTRIS) and with the permission of the study principal investigator (PI). Requests for all collected IPD data from clinical trials, conducted under a binding collaborative agreement between National Cancer Institute (NCI)/Division of Cancer Treatment and Diagnosis (DCTD) and a pharmaceutical/biotechnology company, that are not under Data and Safety Monitoring Board (DSMB) monitoring must be in compliance with the terms of the binding collaborative agreement and must be approved by NCI/DCTD and the Pharmaceutical Collaborator (i.e., the NCI Experimental Therapeutics Clinical Trials Network (ETCTN) Director in conjunction with the NCI/DCTD Regulatory Affairs Branch). Genomic individual participant data (IPD) will be shared through the database of Genotypes and Phenotypes (dbGaP) per rules of the database, for purposes of genomic analysis.
Ran from Apr 2023 to primary completion in Oct 2025, 30 months.
Results were first posted in Oct 2026, 11 months after primary completion.
Of 166 non-industry phase 1 interventional studies under Glioma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 87. This study's 30 months is below that.
Counting every sponsor, half of 213 studies reached it within 59 months; a quarter within 36 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
Drug: Temozolomide · Diagnostic test: Brain MRI · Diagnostic test: Brain CT · Diagnostic test: EKG · Diagnostic test: Chest X-ray · Procedure: Biopsy/resection
Drug: Temozolomide · Diagnostic test: Brain MRI · Diagnostic test: Brain CT · Diagnostic test: EKG · Diagnostic test: Chest X-ray · Procedure: Biopsy/resection
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Abemaciclib · Temozolomide
National Cancer Institute (NCI) →